Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us
About Can-Fite BioPharma About Can-Fite BioPharma About Can-Fite BioPharma About Can-Fite BioPharma About Can-Fite BioPharma

Can-Fite BioPharma (TASE:CFBI; OTC:CANFY) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.

Science
The company technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells. High A3AR expression levels are also >>  more...
Pipeline
Can-Fite has a number of drugs in various stages of research and development. The pipeline drugs are synthetic, highly specific agonists and an allosteric modulator, all target the A3 adenosine receptor. All drugs are orally bioavailable with an excellent >> more...


News
December 30, 2012
Positive Quantitative Interim Analysis Data of the CF101 Psoriasis Phase 2/3 Study >> more...
May 12, 2013
Third Party Presented New Data at the ARVO 2013 Annual Meeting in Seattle, WA, Validating the use of A3 Adenosine Receptor Agonists for Lowering Intra Ocular Pressure and for the Treatment of Glaucoma >> more...

Homepage  |  Contact us    
only canfite.com